Guggenheim Cuts argenex (NASDAQ:ARGX) Price Target to $1,120.00

argenex (NASDAQ:ARGX) had its price objective trimmed by Guggenheim from $1,160.00 to $1,120.00 in a report released on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities research analysts have also issued reports about the stock. Morgan Stanley increased their target price on shares of argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a research note on Thursday, December 4th. Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Wolfe Research restated a “peer perform” rating on shares of argenex in a research report on Monday, November 24th. Robert W. Baird downgraded argenex from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $999.22.

argenex Price Performance

NASDAQ:ARGX opened at $766.92 on Friday. The company has a 50 day moving average price of $826.36 and a 200-day moving average price of $813.13. argenex has a 1-year low of $510.05 and a 1-year high of $934.62. The firm has a market cap of $47.46 billion, a price-to-earnings ratio of 39.29, a price-to-earnings-growth ratio of 1.16 and a beta of 0.38.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.05 by $1.97. The firm had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. argenex had a net margin of 30.42% and a return on equity of 38.51%. On average, sell-side analysts anticipate that argenex will post 3.13 earnings per share for the current fiscal year.

Institutional Trading of argenex

Several large investors have recently made changes to their positions in the company. AQR Capital Management LLC lifted its holdings in argenex by 32.1% in the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after purchasing an additional 122 shares in the last quarter. NewEdge Advisors LLC grew its holdings in shares of argenex by 5,962.5% during the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after buying an additional 1,431 shares in the last quarter. Focus Partners Wealth raised its position in shares of argenex by 22.3% in the first quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after buying an additional 73 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in shares of argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after buying an additional 99 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in argenex by 27.1% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,934 shares of the company’s stock worth $1,066,000 after acquiring an additional 412 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.